Immune Activation and Drug Absorption in HIV-Infected Patients
Status:
Completed
Trial end date:
2016-03-14
Target enrollment:
Participant gender:
Summary
The investigators' objective is to describe the variability of rifampicin absorption, markers
of inflammation and gut damage, intestinal absorptive capacity, and intestinal permeability
among HIV-infected volunteers. Rifampicin is the least well absorbed of the first-line
anti-tuberculosis drugs. Rifampicin malabsorption is frequently observed in HIV-infected
patients with active tuberculosis, but cannot be predicted by patient factors such as CD4+ T
cell count, viral load, or the presence of diarrhea. The mechanisms for rifampicin
malabsorption in HIV-infected patients are unknown. An understanding of mechanisms for
rifampicin malabsorption could eventually lead to new therapeutic targets, with the ultimate
goal of improving HIV/tuberculosis treatment outcomes.